GlycoErase™ SLC35A1 Knockout CHO-K1 Cell Line (CAT#: GLJF-0425-JF78)

Description	The SLC35A1 knockout CHO-K1 cell line investigates SLC35A1 solute carrier family 35 member A1 in CHO-K1 cells as Golgi membrane SLC35A1 transports nucleotide sugars like CMP-sialic acid into the Golgi and the CHO cell SLC35A1 knockout model may disrupt nucleotide sugar transport impacting Golgi glycosylation pathways and CHO cell sialylation.
Product Type	KO Cell Lines
Species	Hamster
Cell Morphology	Epithelial, adherent
Passage Ratio	1:3~1:5
Cell Line	CHO-K1
Lineage	Chinese hamster ovary

Cell Viability	>90%
Sterility Test	The sterility test indicated an absence of microbial growth.
Identity Test	STR identification
Mycoplasma Test	Negative
Virus Test	Negative for HIV, HBV and HCV.
Genetic Stability Testing	We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.
Validation	PCR, Sanger Sequencing
Culture Medium	FBS & Penicillin/Streptomycin & Proline & RPMI
Application	Functional assay
Size	1 M cells/vial*2
Product Format	Frozen
Shipping	Dry ice
Availability Status	Made to order
Handling Notes	Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.
Product Disclaimer	This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.

Target	SLC35A1
Full Name	Solute carrier family 35 member A1
Alternative Name	CMP-Sia-Tr, hCST, CMPST
Gene ID	10559
Summary	Transports nucleotide sugars, including CMP-sialic acid, into the Golgi apparatus for glycosylation; defects cause congenital disorder of glycosylation type 2F (CDG2F).